Goldman Sachs Healthcare Stocks: Top 10 Stock Picks

8. AstraZeneca PLC (NASDAQ:AZN)

Goldman Sachs Equity Stake: $865.97 Million

Number of Hedge Fund Holders: 56

AstraZeneca PLC (NASDAQ:AZN) is one of Goldman Sachs’ top healthcare stock picks. On July 4, the company secured regulatory approval for Imfinzi (durvalumab). The approval is for the use of the drug for the treatment of muscle-invasive bladder cancer (MIBC).

The regulatory approval by the European Commission follows a positive opinion by the Committee for Medicinal Products for Human Use. It also comes on the heels of the company delivering positive results from the NIAGARA Phase III trial.

“The NIAGARA results showed how this regimen reduced the risk of recurrence by nearly a third and significantly extended survival, underscoring its potential to transform clinical practice in this curative-intent setting,” Dr. Michiel Van der Heijden, medical oncologist and Group Leader at the Netherlands Cancer Institute, and investigator in the NIAGARA trial, said.

With the regulatory approval, AstraZeneca stands to target over 30,000 people in the five major European countries struggling with respectable muscle-invasive bladder cancer (MIBC).

AstraZeneca PLC (NASDAQ:AZN) is a biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. It operates in key therapeutic areas, including oncology, cardiovascular, renal, and metabolic diseases, as well as respiratory, immunology, and rare diseases.